Oleg Bess, MD, explains why data quality is essential to improving the United States health care system.
Preetesh Jain, MD, PhD, discusses ongoing research efforts in mantle cell lymphoma.
Deborah B. Doroshow, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on cancer care.
Breast medical oncologists close out the program on HR+ metastatic breast cancer by highlighting ongoing clinical trials with antibody-drug conjugate therapy.
Dr Joseph Mikhael and expert panel review current treatment options for patients with early relapse multiple myeloma, in accordance with current NCCN guidelines.
Nilay Shah, MD, discusses the significance of the approval of sodium thiosulfate for pediatric patients with cisplatin-treated pediatric solid tumors.
Dr. Waguespack reviews efficacy and safety data for larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
Drs Josep Llovet, Stephen L. Chan, and Andrea Casadei Gardini discuss the future treatment landscape for HCC.
Shumei Kato, MD, discusses the characterization of BRAF mutations in oncology.
Madan L. Arora, MD, discusses the evolution of treatment in follicular lymphoma.
Evan J. Lipson, MD, discusses the effect of preoperative nivolumab plus relatlimab in resectable non-small cell lung cancer (NSCLC).
Georges Azzi, MD, co-director, Department of Hematology/Oncology, Prostate Cancer, Holy Cross Health, discusses the utilization of the Signatera circulating tumor DNA assay in the ongoing phase 2/3 CIRCULATE-US trial in colorectal cancer.
Vineet Talwar, DM, FRCP, DNB, FICP, FIMSA, MNAMS, discusses the utility of immunotherapy in metastatic urothelial carcinoma.
Usman Ali Akbar, MD, discusses the systematic review of the efficacy of monoclonal antibodies in adult patients with relapsed/refractory acute lymphoblastic leukemia.
Chan Cheah, MBBS, discusses the investigation of BGB-11417 with or without zanubrutinib in chronic lymphocytic leukemia.
Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.
Jason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.
Anant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.
Institutional Perspectives in Cancer- GI: Chaired by Anne M Noonan, MBBCh
Kevin Zarrabi, MD, discusses an analysis of real-world outcomes with axitinib plus pembrolizumab vs ipilimumab plus nivolumab in patients with metastatic clear cell renal cell carcinoma.
Susan Faye Dent, MD, discusses the clinical implications of the phase 3 MONALEESA-2 trial in hormone receptor–positive, HER2-negative breast cancer.
Martine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.
Closing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.
John L. Hays, MD, PhD, discusses the importance of clinical trials in colorectal cancer.
The coronavirus disease 2019 crisis has changed all aspects of medical education but perhaps altered clinical education most dramatically.
Lakshmi Rajdev, MD, MS, discusses detecting HER2 positivity in patients with gastrointestinal cancers.
During the past several decades, cancer research has produced revolutionary discoveries leading to dramatic results for many patients.
Brian Ramnaraign, MD, discusses the evaluation of atezolizumab plus tivozanib in a phase 1b/2 trial in patients with pancreatic, gallbladder, and bile duct cancers.
Kim E. Nichols, MD, discusses the prognosis of patients with von Hippel-Lindau disease.